Table 2. The subgroup analyses for the association between CAR and OS and CSS in gastric cancer.

Subgroups	No. of studies	No. of patients	Fixed-effects model		Random-effects model		Heterogeneity
			HR (95%CI)	p	HR (95%CI)	p	I2(%)	Ph
OS
Total	6	2,127	1.59(1.36–1.85)	<0.001	1.59(1.36–1.85)	<0.001	0	0.628
Country
China	3	1,050	1.51(1.26–1.80)	<0.001	1.51(1.26–1.80)	<0.001	0	0.414
Japan	3	1,077	1.86(1.36–2.55)	<0.001	1.86(1.36–2.55)	<0.001	0	0.811
Treatment
Surgery	4	1,532	1.74(1.39–2.17)	<0.001	1.74(1.39–2.17)	<0.001	0	0.856
Mixed	1	337	1.78(1.20–2.65)	0.004	1.78(1.20–2.65)	0.004	-	-
Chemotherapy	1	258	1.33(1.03–1.73)	0.030	1.33(1.03–1.73)	0.030	-	-
Cut-off value
<0.2	3	1,077	1.86(1.36–2.55)	<0.001	1.86(1.36–2.55)	<0.001	0	0.811
≥0.2	3	1,050	1.51(1.26–1.80)	<0.001	1.51(1.26–1.80)	<0.001	0	0.414
TNM stage
I-III	2	839	1.73(1.31–2.28)	<0.001	1.73(1.31–2.28)	<0.001	0	0.386
IV	1	258	1.33(1.03–1.73)	0.030	1.33(1.03–1.73)	0.030	-	-
I-IV	2	790	1.79(1.30–2.45)	<0.001	1.79(1.30–2.45)	<0.001	0	0.977
II	1	240	1.71(1.02–2.87)	0.043	1.71(1.02–2.87)	0.043	-	-
CSS
Total	3	1,473	1.65(1.21–2.25)	0.002	1.65(1.21–2.25)	0.002	0	0.919
Country
China	2	1,089	1.58(1.09–2.29)	0.015	1.58(1.09–2.29)	0.015	0	0.923
Japan	1	384	1.82(1.03–3.22)	0.040	1.82(1.03–3.22)	0.040	-	-
Treatment
Surgery	2	785	1.76(1.05–2.95)	0.033	1.76(1.05–2.95)	0.033	0	0.775
Mixed	1	688	1.59(1.08–2.35)	0.019	1.59(1.08–2.35)	0.019	-	-
Cut-off value
<0.2	2	785	1.76(1.05–2.95)	0.033	1.76(1.05–2.95)	0.033	0	0.775
≥0.2	1	688	1.59(1.08–2.35)	0.019	1.59(1.08–2.35)	0.019	-	-
TNM stage
I-III	2	785	1.76(1.05–2.95)	0.033	1.76(1.05–2.95)	0.033	0	0.775
II-III	1	688	1.59(1.08–2.35)	0.019	1.59(1.08–2.35)	0.019	-	-